

Asia Cervical Cancer Diagnostic Market, By Test Type (Pap smear, HPV DNA and VIA), Countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) & Forecast

<https://marketpublishers.com/r/A0F94200DD7EN.html>

Date: June 2018

Pages: 0

Price: US\$ 1,290.00 (Single User License)

ID: A0F94200DD7EN

Abstracts

Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. Cervical cancer diagnostic market in Asian region is growing and expected to cross over USD 1 Billion by 2024. Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus. Despite declining women population, Japan has highest market share in cervical cancer test market. Whereas Indonesia is dominating in cervical cancer testing population followed by China.

Growing women population, rising sum of structured cervical cancer programs introduced by governments and international NGOs and inception of low cost VIA test are some of the major growth drivers for the growth of cervical cancer test market in the developing countries.

Renub Research report titled “Asia Cervical Cancer Diagnostic Market, By Test Type (Pap smear, HPV DNA and VIA), Countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) & Forecast” provides a complete analysis of Asia Cervical Cancer Screening Market. The report provides a complete analysis of Asia Countries Cervical Cancer Test Market, Screened Population & Mortality.

By Test Types – Pap smear Screening Tests is gaining popularity in Asia, although VIA has bright future due to its lower cost characteristic.

The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests, HPV DNA Tests and VIA Tests. Pap smears and VIA tests is more popular with the developing countries such as India, China, and Indonesia.

By Country – Indonesia and China holds the largest share by Population

The report studies the market/screened population of Eight big Asian countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) which provides a complete country-wise analysis of Asia Cervical Cancer Screening Market.

All the 8 Asian countries in the report have been studied from 3 viewpoints.

Cervical Cancer Diagnostic Market

Pap Smear Tests Market

HPV DNA Tests Market

VIA Tests Market

Cervical Cancer Test Population

Pap Smear Test Population

HPV DNA Test Population

VIA Test Population

Cervical Cancer Mortality Population

Japan

Korea

All the 8 Countries Studied in the Report are as Follows

Japan

Korea

Singapore

Malaysia

India

China

Thailand

Indonesia

Contents

1. EXECUTIVE SUMMARY

2. ASIA CERVICAL CANCER TEST (SCREENING) ANALYSIS

2.1 Asia Cervical Cancer Test Population

2.1.1 Pap smear Test Population

2.1.2 HPV DNA Test Population

2.1.3 VIA Test Population

2.2 Asia Cervical Cancer Test (Screening) Market

2.2.1 Pap Smear Test Market

2.2.2 HPV DNA Test Market

2.2.3 Visual Inspection with Acetic Acid (VIA) Test Market

3. MARKET & POPULATION SHARE – BY COUNTRIES

3.1 Asia Cervical Cancer Test Population

3.1.1 Pap Smear Population

3.1.2 HPV DNA Population

3.1.3 VIA Population

3.2 As Market Share – By Countries

3.2.1 Pap Smear Market

3.2.2 HPV DNA Market

3.2.3 VIA Market

4. JAPAN – CERVICAL CANCER TEST ANALYSIS

4.1 Population - Cervical Cancer Test (Screening)

4.1.1 Pap smear Test Population

4.1.2 HPV DNA Test Population

4.2 Japan Cervical Cancer Mortality

4.3 Market – Cervical Cancer Test (Screening)

4.3.1 Pap Smear Test Market

4.3.2 HPV DNA Test Market

5. SOUTH KOREA – CERVICAL CANCER TESTS ANALYSIS

5.1 Population – Cervical Cancer Test (Screening)

- 5.1.1 Pap Smear Test Population
- 5.1.2 HPV DNA Test Population
- 5.2 Korea Cervical Cancer Mortality
- 5.3 Market – Cervical Cancer Test (Screening)
 - 5.3.1 Pap Smear Test Market
 - 5.3.2 HPV DNA Test Market

6. SINGAPORE – CERVICAL CANCER TESTS ANALYSIS

- 6.1 Population – Cervical Cancer Test (Screening)
 - 6.1.1 Pap Smear Test Population
 - 6.1.2 HPV DNA Test Population
- 6.2 Market – Cervical Cancer Test (Screening)
 - 6.2.1 Pap Smear Test Market
 - 6.2.2 HPV DNA Test Market

7. MALAYSIA – CERVICAL CANCER TEST ANALYSIS

- 7.1 Population – Cervical Cancer Test (Screening)
 - 7.1.1 Pap Smear Test Population
 - 7.1.2 HPV DNA Test Population
- 7.2 Market – Cervical Cancer Test (Screening)
 - 7.2.1 Pap Smear Test Market
 - 7.2.2 HPV DNA Test Market

8. INDIA – CERVICAL CANCER TEST ANALYSIS

- 8.1 Population – Cervical Cancer Test (Screening)
 - 8.1.1 Pap Smear Test Population
 - 8.1.2 HPV DNA Test Population
 - 8.1.3 VIA Test Population
- 8.2 Market – Cervical Cancer Test (Screening)
 - 8.2.1 Pap Smear Test Market
 - 8.2.2 HPV DNA Test Market
 - 8.2.3 VIA Test Market

9. CHINA – CERVICAL CANCER TEST ANALYSIS

- 9.1 Population – Cervical Cancer Test (Screening)

- 9.1.1 Pap Smear Test Population
- 9.1.2 HPV DNA Test Population
- 9.1.3 VIA Test Population
- 9.2 Market – Cervical Cancer Test (Screening)
 - 9.2.1 Pap Smear Test Population
 - 9.2.2 HPV DNA Test Population
 - 9.2.3 VIA Test Market

10. THAILAND – CERVICAL CANCER TEST ANALYSIS

- 10.1 Population – Cervical Cancer Test (Screening)
 - 10.1.1 Pap Smear Test Population
 - 10.1.2 VIA Test Population
- 10.2 Market – Cervical Cancer Test (Screening)
 - 10.2.1 Pap Smear Test Market
 - 10.2.2 VIA Test Market

11. INDONESIA – CERVICAL CANCER TEST ANALYSIS

- 11.1 Population – Cervical Cancer Test (Screening)
 - 11.1.1 Pap Smear Test Population
 - 11.1.2 HPV DNA Test Population
 - 11.1.3 VIA Test Population
 - 11.1.4 Pap smear & VIA Test Population
- 11.2 Market – Cervical Cancer Test (Screening)
 - 11.2.1 Pap smear Test Market
 - 11.2.2 HPV DNA Test Market
 - 11.2.3 VIA Test Market
 - 11.2.4 Pap smear & VIA Test Market

12. GROWTH DRIVERS

- 12.1 Introduction of Low Cost VIA Test
 - 12.1.1 Countries Offering VIA Test via National Programs
 - 12.1.2 Countries Offering VIA Test via Pilot Programs
- 12.2 Worldwide Rising Incidence of Teenage Sexual Cases
- 12.3 Worldwide High Prevalence of HPV Infected Patients

13. CHALLENGES

13.1 Lack of Appropriate Healthcare Infrastructure

13.2 Introduction of HPV Vaccination Programs Worldwide

List Of Figures

LIST OF FIGURES:

Figure 2-1: Asia – Cervical Cancer Test Population (Million), 2011 – 2017

Figure 2-2: Asia – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024

Figure 2-3: Asia – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017

Figure 2-4: Asia – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024

Figure 2-5: Asia – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017

Figure 2-6: Asia – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024

Figure 2-7: Asia – Cervical Cancer VIA Test Population (Million), 2011 – 2017

Figure 2-8: Asia – Forecast for Cervical Cancer VIA Test Population (Million), 2018 – 2024

Figure 2-9: Asia – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 2-10: Asia – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 2-11: Asia – Cervical Cancer Pap smear Test Market (Million US\$), 2011 – 2017

Figure 2-12: Asia – Forecast for Cervical Cancer Pap smear Test Market (Million US\$), 2018 – 2024

Figure 2-13: Asia – Cervical Cancer HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 2-14: Asia – Forecast for Cervical Cancer HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 2-15: Asia – Cervical Cancer VIA Test Market (Million US\$), 2011 – 2017

Figure 2-16: Asia – Forecast for Cervical Cancer VIA Test Market (Million US\$), 2018 – 2024

Figure 3-1: Asia – Cervical Cancer Test Population Share (%), 2011 – 2017

Figure 3-2: Asia – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024

Figure 3-3: Asia – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017

Figure 3-4: Asia – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024

Figure 3-5: Asia – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017

Figure 3-6: Asia – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024

Figure 3-7: Asia – Cervical Cancer VIA Test Population Share (%), 2011 – 2017

Figure 3-8: Asia – Forecast for Cervical Cancer VIA Test Population Share (%), 2018 – 2024

Figure 3-9: Asia – Cervical Cancer Test Market Share (%), 2011 – 2017

Figure 3-10: Asia – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024

Figure 3-11: Asia – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017

Figure 3-12: Asia – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024

Figure 3-13: Asia – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017

Figure 3-14: Asia – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024

Figure 3-15: Asia – cervical cancer VIA Test Market Share (%), 2011 – 2017

Figure 3-16: Asia – Forecast for cervical cancer VIA Test Market Share (%), 2018 – 2024

Figure 4-1: Japan – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 4-2: Japan – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 4-3: Japan – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 4-4: Japan – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 4-5: Japan – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017

Figure 4-6: Japan – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024

Figure 4-7: Japan – Cervical Cancer Mortality (Number), 2011 – 2017

Figure 4-8: Japan – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 4-9: Japan – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 4-10: Japan – Pap Smear Test Market (Million US\$), 2011 – 2017

Figure 4-11: Japan – Forecast for Pap Smear Test Market (Million US\$), 2018 – 2024

Figure 4-12: Japan – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 4-13: Japan – Forecast for HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 5-1: Korea – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 5-2: Korea – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 5-3: Korea – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 5-4: Korea – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 5-5: Korea – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017

Figure 5-6: Korea – Forecast for Cervical Cancer HPV DNA Test Population

(Thousand), 2018 – 2024

Figure 5-7: Korea – Cervical Cancer Mortality (Number), 2011 – 2017

Figure 5-8: Korea – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 5-9: Korea – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 5-10: Korea – Pap Smear Test Market (Million US\$), 2011 – 2017

Figure 5-11: Korea – Forecast for Pap Smear Test Market (Million US\$), 2018 – 2024

Figure 5-12: Korea – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 5-13: Korea – Forecast for HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 6-1: Singapore – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 6-2: Singapore – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 6-3: Singapore – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 6-4: Singapore – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 6-5: Singapore – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017

Figure 6-6: Singapore – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024

Figure 6-7: Singapore – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 6-8: Singapore – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 6-9: Singapore – Pap Smear Test Market (Million US\$), 2011 – 2017

Figure 6-10: Singapore – Forecast for Pap Smear Test Market (Million US\$), 2018 – 2024

Figure 6-11: Singapore – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 6-12: Singapore – Forecast for HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 7-1: Malaysia – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 7-2: Malaysia – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 7-3: Malaysia – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 7-4: Malaysia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 7-5: Malaysia – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017

Figure 7-6: Malaysia – Forecast for Cervical Cancer HPV DNA Test Population

(Thousand), 2018 – 2024

Figure 7-7: Malaysia – Cervical Cancer Test Market (Million US\$), 2011– 2017

Figure 7-8: Malaysia – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 7-9: Malaysia – Pap smear Test Market (Million US\$), 2011 – 2017

Figure 7-10: Malaysia – Forecast for Pap smear Test Market (Million US\$), 2018 – 2024

Figure 7-11: Malaysia – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 7-12: Malaysia – Forecast for HPV DNA Test Market (Million US\$), 2018– 2024

Figure 8-1: India – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 8-2: India – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 8-3: India – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 8-4: India – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 8-5: India – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017

Figure 8-6: India – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024

Figure 8-7: India – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017

Figure 8-8: India – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024

Figure 8-9: India – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 8-10: India – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 8-11: India – Pap smear Test Market (Million US\$), 2011 – 2017

Figure 8-12: India – Forecast for Pap smear Test Market (Million US\$), 2018 – 2024

Figure 8-13: India – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 8-14: India – Forecast for HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 8-15: India – VIA Test Market (Million US\$), 2011 – 2017

Figure 8-16: India – Forecast for VIA Test Market (Million US\$), 2018 – 2024

Figure 9-1: China – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 9-2: China – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 9-3: China – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 9-4: China – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 9-5: China – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017

Figure 9-6: China – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024

Figure 9-7: China – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017

Figure 9-8: China – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024

Figure 9-9: China – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 9-10: China – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 9-11: China – Pap smear Test Market (Million US\$), 2011 – 2017

Figure 9-12: China – Forecast for Pap Smear Test Market (Million US\$), 2018 – 2024

Figure 9-13: China – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 9-14: China – Forecast for HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 9-15: China – VIA Test Market (Million US\$), 2011 – 2017

Figure 9-16: China – Forecast for VIA Test Market (Million US\$), 2018 – 2024

Figure 10-1: Thailand – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 10-2: Thailand – Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 10-3: Thailand – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 10-4: Thailand – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 10-5: Thailand – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017

Figure 10-6: Thailand – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024

Figure 10-7: Thailand – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 10-8: Thailand – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 10-9: Thailand – Pap smear Test Market (Million US\$), 2011 – 2017

Figure 10-10: Thailand – Forecast for Pap Smear Test Market (Million US\$), 2018 – 2024

Figure 10-11: Thailand – VIA Test Market (Million US\$), 2011 – 2017

Figure 10-12: Thailand – Forecast for VIA Test Market (Million US\$), 2018 – 2024

Figure 11-1: Indonesia – Cervical Cancer Test Population (Thousand), 2011 – 2017

Figure 11-2: Indonesia – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024

Figure 11-3: Indonesia – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017

Figure 11-4: Indonesia – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024

Figure 11-5: Indonesia – Cervical Cancer HPV DNA Test Population (Thousand), 2011

– 2017

Figure 11-6: Indonesia – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024

Figure 11-7: Indonesia – Cervical Cancer VIA Test Population (Thousand), 2011 – 2017

Figure 11-8: Indonesia – Forecast for Cervical Cancer VIA Test Population (Thousand), 2018 – 2024

Figure 11-9: Indonesia – Cervical Cancer Both (Pap smear & VIA) Test Population (Thousand), 2011 – 2017

Figure 11-10: Indonesia – Forecast for Cervical Cancer Both (Pap smear & VIA) Test Population (Thousand), 2018 – 2024

Figure 11-11: Indonesia – Cervical Cancer Test Market (Million US\$), 2011 – 2017

Figure 11-12: Indonesia – Forecast for Cervical Cancer Test Market (Million US\$), 2018 – 2024

Figure 11-13: Indonesia – Pap Smear Test Market (Million US\$), 2011 – 2017

Figure 11-14: Indonesia – Forecast for Pap Smear Test Market (Million US\$), 2018 – 2024

Figure 11-15: Indonesia – HPV DNA Test Market (Million US\$), 2011 – 2017

Figure 11-16: Indonesia – Forecast for HPV DNA Test Market (Million US\$), 2018 – 2024

Figure 11-17: Indonesia – VIA Test Market (Million US\$), 2011 – 2017

Figure 11-18: Indonesia – Forecast for VIA Test Market (Million US\$), 2018 – 2024

Figure 11-19: Indonesia – Both (Pap smear & VIA) Test Market (Million US\$), 2011 – 2017

Figure 11-20: Indonesia – Forecast for Both (Pap smear & VIA) Test Market (Million US\$), 2018 – 2024

List Of Tables

LIST OF TABLES:

Table 12 1: Worldwide – List of Countries which offer VIA Test via National Programs, 2015

Table 12 2: Worldwide – List of Countries which offer VIA Test via Pilot Programs, 2015

Table 12 3: Worldwide – Prevalence (Percent) of Young Women (15–44 Years) who Have Sex before the Age of 15 Years, 1994 – 2006

Table 12 4: Worldwide – Prevalence of HPV 16/18 in Women with Normal Cervical Cytology (Percent), 2014 - 2015

I would like to order

Product name: Asia Cervical Cancer Diagnostic Market, By Test Type (Pap smear, HPV DNA and VIA), Countries (Japan, Korea, Singapore, Malaysia, India, China, Thailand and Indonesia) & Forecast

Product link: <https://marketpublishers.com/r/A0F94200DD7EN.html>

Price: US\$ 1,290.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0F94200DD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970